DOCTORS'
Medical Case Studies
DOCTORS'
Medical Case Studies
Monoclonal antibody therapy
Monoclonal antibody therapy
Monoclonal antibody therapy is the use of monoclonal antibodies (or mAb) to specifically bind to target cells. This may then stimulate the patient's immune system to attack those cells. It is possible to create a mAb specific to almost any extracellular/ cell surface target, and thus there is a large amount of research and development currently being undergone to create monoclonals for numerous serious diseases. There are a number of ways that mAbs can be used for therapy. For example: mAb therapy can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors...
Monoclonal antibody therapy - List of case studies
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)_2
-
2) What therapy do you suggest? In case the therapy performed is the best one could you ... amyotrophic lateral sclerosis, paraprotein, anti-MAG antibody, guillian-barre syndrome, etc. To further evaluate, would ... Rituximab a monoclonal anti-CD20 antibody against B-cells maybe an effective option for ...
- Drugs
-
Blocker (ARB) Anthracyclines Anti CTLA-4 monoclonal anti-bodies Anti aggregating agent Anti-cholinergic ... supplements Anti-platelet therapy Antiangiogenic antibody Avastin Antiarrhythmic treatment Antibiotic Antibiotic ...
- Thrombotic thrombocytopenic purpura (TTP) secondary to Systemic Lupus Erythematosus (SLE)
-
systemic disease is coexistent with the TTP? 2. The antibody for ADAMTS13 was negative after 12 sessions of PEX (in total 15 were ... (1000 ml) for 4 days; the administration of anti-CD20 monoclonal antibody (Rituximab) started and 4 infusions were carried out at a ...
- Clear Cell Carcinoma of the Kidney
-
months or participating in an adjuvant vaccine trial or monoclonal antibody therapy trial. questions: ...
- Operated breast cancer with metastases
-
as compared with Trastuzumab which is a large molecular monoclonal antibody that does not cross the BBB. - If progression is exclusively ...